Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Climb Bio, Inc.

35 indications, side-by-side phase, drug & LoA

$11.44

+0.53 (+4.86%)

C 43Pipeline Score Fair Value Biotech · Commercial
Market Cap
629.87 M
EPS
-0.78
P/E Ratio
-
Value Trade
13.87 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • R&D Expenses

    9.37 M

  • Operating CF

    -14.38 M

  • Total Assets

    152.37 M

  • Total Liabilities

    4.29 M

  • Equity

    148.09 M

  • D/E Ratio

    12,345

-0.36 %
Week
16.28 %
1 Month
97.13 %
3 Month
539.53 %
6 Month
-32.31 %
5 Year
-32.31 %
All Time
Cash Data
Stable

  • Cash Position

    109.56 M

  • Monthly Burn

    4.79 M

  • Runway

    21.8 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 7, 2026
Overview
Volume
858.99 K
52 Week Range
1.16 - 12.48
% held by Insiders
16.8 %
% held by Institutions
64.33 %
Enterprise Value
520.78 M
Total Shares
47.73 M
Short %
4.01 %
Float Shares
19.95 M
Company Description
HQ: 20 WILLIAM STREET, WELLESLEY H...
Employees:29
https://www.climbbio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1b/2a data readout example
budoprutug primary immune thrombocytopenia (ITP)
Phase 1b/2a
—
Biologics
Hematologic System
budoprutug primary immune thrombocytopenia (ITP)
Phase 1b/2a
—
Biologics
Hematologic System
budoprutug primary immune thrombocytopenia (ITP)
Phase 1b/2a
—
Biologics
Hematologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C43
Pipeline Score
$230M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
1.2x
rNPV / MCap
Top 59%
Micro Cap
(rank 372 of 905)
Percentile Rank
Climb Bio, Inc. carries a moderate pipeline score (43/100), with $931M risk-adjusted pipeline value, led by Budoprutug in Systemic Lupus Erthematosus (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
budoprutug
Small molecule		Primary Membranous NephropathyPhase 2NCT0709684354% $398M RECRUITING 45 AVERAGE C (42) Oct 1, 2027MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
CLYM116
IgA nephropathy
Preclinical
2025-09-30
CLYM116
IgA nephropathy
Preclinical
2025-09-30
CLYM116
IgA nephropathy
Preclinical
2025-09-30
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CLYM
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CLYM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CLYM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CLYM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CLYM Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CLYM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-11-20 0.00 0 - - - - - -
2026-11-20 0.00 0 - - - - - -
2026-11-20 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Climb Bio, Inc. (CLYM) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CLYM ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Membranous Nephropathy #6 of 7 PHASE 2 budoprutug
BIIB NVS ONC
$0.39B 0.88 FOLLOWER
Thrombocytopenia #15 of 18 PHASE 1 Budoprutug
NVS TAK ARGX
$1.85B 0.82 FOLLOWER
Systemic Lupus Erythematosus #25 of 32 PHASE 1 Budoprutug
BIIB VTRS BMY
$2.78B 0.85 FOLLOWER
Lymphoma #44 of 69 PHASE 1 Budoprutug
REGN LLY MRK
$8.52B 0.82 FOLLOWER